April 13, 2023

Siddhartha Shrivastava - Vice President, Head of CMC and Global Technical Operations - Cue Biopharma

In this episode of Life Science Success my guest is Siddhartha Shrivastava, Ph.D.  Sidd is the  Vice President, Head of CMC and Global Technical Operations at Cue Biopharma.  He is a proven leader and well-published scientific-technical...

In this episode of Life Science Success my guest is Siddhartha Shrivastava, Ph.D.  Sidd is the 
Vice President, Head of CMC and Global Technical Operations at Cue Biopharma.  He is a proven leader and well-published scientific-technical operations professional with experience in leading research, early to late-stage process development, commercial launch, cGMP commercial manufacturing (DS/DP), due diligence of new targets and facility acquisition, end to end supply chain management, and CMO management for bio-therapeutic drugs.

Introduction

 

03:12 Tell listeners a little bit about yourself.

09:16 So can you tell us what the typical day is like for you as the vice president and Head of CMC and Global Technical Operations at Cue Biopharma?

15:31 So you were at Thermo and Sanofi, prior to your time at Cue Biopharma. How did that experience prepare you for what you're doing now? 

20:58 Who is Cue Biopharma and what is it that they do? What sort of products do they do?

29:28 So, whenever you mentioned the autoimmune things you would target, what sort of targets do you have for autoimmune diseases?

35:19 There are some questions that I like to ask every guest.

-What Inspires you?

40:00 -What concerns you? 

42:15 -What excites you? 

Please check out our Life Science Success Resources.  You will find tools that will support growing companies and books for authors I have interviewed.  

Siddhartha Shrivastava, PhDProfile Photo

Siddhartha Shrivastava, PhD

Vice President, Head of CMC and Global Technical Operations

Sidd is proven leader and well published scientific technical operations executive with track record of bringing and maintaing lifecyle of lifesaving drugs globally. Some of the biologic drugs that Sidd managed include-Remicade®, Stelara®, ATryn®, Cerezyme®, Fabrazyme®, Thyrogen®, rhASM® , Praluent®, Dupilumab® ; like wise few of the small molecule drugs managed by him include- Allegra®, Proctosedyl®, Flomax®, Elegard®, Primaquine®, Duexis®, Cholestagel®, Nicoderm®, Zinquesta®, Glyburide® etc.

He is member of executive leadership responsible and partnering in creating and implementing business plans and strategies, achieving company’s financial goals and network wide objectives along with increasing network operating performance. Have maintained multi billion $$ franchise portfolio for top global pharmaceutical producers like Sanofi and on the other hand have also helped establish new biotech and CMO-CDMOs.

Experienced in leading research, early to late-stage process development, commercial launch, cGMP commercial manufacturing (DS/DP) and reprocessing of bio-therapeutic drugs. Seasoned in developing, leading, transforming and sustaining multisite high-performance matrix organizations and teams. Accomplished leader in process development and manufacturability assessment; CMC program management; CMO management for Phase I/II/III clinical trial material and commercial manufacturing; Assets and partnering due diligence, Establishing new PD, analytical and commercial manufacturing facilities; IND/IMPD, BLA/MAA regulatory filings and product life-cycle… Read More